US Tumor Ablation Market (2026-2031)
The US Tumor Ablation Market was valued at $402.6 Million in 2026 and projected to reach to $665.2 Million by 2031, representing a compound annual growth rate of 10.6%. The US tumor ablation market is poised for sustained growth through 2031, driven by increasing adoption of minimally invasive procedures among US healthcare providers and patients seeking alternatives to traditional surgery.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Tumor Ablation Market Trends and Insights
- This expansion reflects the US healthcare system's increasing adoption of minimally invasive ablation technologies for cancer treatment.
- The US market benefits from advanced healthcare infrastructure, high patient awareness, and strong reimbursement frameworks that support the deployment of cutting-edge ablation devices across hospitals and outpatient centers. Driving this growth, the US market is characterized by rising incidence of solid tumors, growing preference for image-guided interventional procedures, and continuous technological innovation in radiofrequency, microwave, and cryoablation systems.
- The US regulatory environment, led by the FDA, ensures rapid approval pathways for novel ablation technologies, enabling manufacturers to bring advanced solutions to market quickly.
- Between 2026 and 2031, the US is expected to maintain its position as a leading market for tumor ablation, supported by increasing clinical evidence, expanding clinical applications, and growing investment in interventional oncology infrastructure..
Key Market Statistics
- CAGR (2026-2031) 10.6% CAGR
- Market Size, 2026 ~USD 402.6 Million
- Forecast, 2031 ~USD 665.2 Million
- Country US
US Tumor Ablation Market Overview
Market Valuation Growth :
The US tumor ablation market is valued at $402.6 million in 2026 and is projected to reach $665.2 million by 2031, representing a robust 10.6% CAGR over the forecast period.
Advanced Healthcare Infrastructure :
The US benefits from state-of-the-art medical facilities, cutting-edge technology adoption, and a well-established healthcare ecosystem that accelerates the deployment of minimally invasive ablation solutions.
Strong Reimbursement Framework :
Favorable insurance coverage and Medicare reimbursement policies in the US support widespread adoption of tumor ablation procedures, reducing patient out-of-pocket costs and driving market expansion.
High Patient Awareness :
US patients demonstrate elevated awareness of minimally invasive cancer treatment options, supported by extensive healthcare education, digital health resources, and physician advocacy for ablation technologies.
US Tumor Ablation Market Dynamics
- Technological advancements in radiofrequency, microwave, and cryoablation systems are expanding treatment applications across oncology centers and hospitals nationwide. Key growth catalysts include rising cancer incidence rates, aging population demographics, and continued investment in interventional radiology infrastructure.
- The US market's maturity and regulatory clarity position it as a leader in ablation technology innovation, with strong competition among device manufacturers driving product improvements and market penetration across urban and emerging healthcare markets..
Market Ecosystem
TUMOR ABLATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides radiofrequency (RF) ablation systems that use controlled thermal energy to destroy solid tumors by inducing localized coagulative necrosis. These systems are widely used for the minimally invasive treatment of liver, kidney, lung, bone, and soft tissue tumors through surgical, laparoscopic, or percutaneous procedures in hospitals and cancer centers. | Delivers precise and controlled tumor destruction while preserving surrounding healthy tissue, enables minimally invasive treatment, reduces blood loss and hospital stay, supports faster patient recovery, and provides reliable clinical outcomes across multiple tumor indications. |
 |
Provides cryoablation systems that utilize extremely low temperatures to freeze and destroy cancerous tissue. These systems are commonly used to treat kidney, liver, lung, bone, and soft tissue tumors through image-guided, minimally invasive procedures performed in interventional radiology and oncology departments. | Enables precise visualization of the ablation zone, minimizes damage to adjacent healthy tissue, reduces procedural pain, supports preservation of critical structures, shortens recovery time, and delivers effective local tumor control with predictable treatment outcomes. |
 |
Provides robotic high-intensity focused ultrasound (HIFU) systems for non-invasive focal treatment of localized prostate cancer. The platform combines robotic targeting, real-time imaging, and focused ultrasound energy to precisely ablate cancerous tissue without surgical incisions, making it suitable for urology and specialized cancer centers | Offers completely incision-free treatment, preserves surrounding healthy tissue and urinary/sexual function, improves targeting accuracy through robotic assistance, reduces procedure-related complications, shortens recovery time, and enhances patient quality of life following treatment |
 |
Provides radiofrequency ablation electrodes designed to accurately deliver RF energy from the generator to targeted tumor tissue during ablation procedures. These disposable electrodes are used in conjunction with RF ablation systems for treating liver, kidney, lung, bone, and other solid tumors in minimally invasive oncology procedures. | Ensures efficient and uniform energy delivery, improves ablation accuracy, supports consistent lesion formation, enhances procedural safety, minimizes collateral tissue damage, and contributes to successful local tumor destruction with reliable clinical performance |
 |
Provides radiofrequency ablation systems that generate controlled thermal energy for the treatment of solid tumors during open, laparoscopic, and percutaneous procedures. These systems are utilized in oncology, general surgery, and interventional radiology settings to perform minimally invasive tumor ablation across multiple cancer indications | Provides stable and precise energy delivery for effective tumor destruction, improves procedural efficiency, supports minimally invasive treatment, reduces post-operative complications and recovery time, and offers dependable performance for a broad range of tumor ablation procedures |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Diagnostic Imaging
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- CT Scanners
- Nuclear Imaging
- Positron Emission Tomography
- Siemens healthineers
- PHILIPS HEALTHCARE
- CANON INC.
- FUJIFILM Holdings Corporation
- UNITED IMAGING HEALTHCARE CO., LTD.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- The US tumor ablation market will grow from $402.6M (2026) to $665.2M (2031), representing a 10.6% CAGR.
- The US market is driven by rising solid tumor incidence, minimally invasive procedure adoption, and strong FDA regulatory support.
- The US healthcare infrastructure and reimbursement landscape provide competitive advantages for ablation technology deployment.
- The US market will see expanded clinical applications and increased interventional oncology investment through 2031.
Tumor Ablation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CANCER CARE CENTERS (End User) |
| Forecast Period | 2026-2031 |
| Growth Rate | CAGR of 11.4% from 2026 to 2031 |
| Largest Segment | HOSPITALS & CLINICS (End User) |
| Market Size Base Year (Billions) | ~USD 1.1 (2026) |
| Revenue Forecast (Billions) | ~USD 1.89 (2031) |
| Segments Covered | Technology, Product Type, Type, Procedure, Application, End User |
US Tumor Ablation Market Report Segmentation
6 segment dimensions are covered across the global market.
By Technology
- Cryoablation
- Ire
- Mwa
- Other Technologies
- Rfa
By Product Type
- Consumables & Accessories
- Systems
By Type
- Cryoablation Systems
- Ire Systems
- Mwa Probes
- Mwa Systems
- Other Consumables & Accessories
- Other Probes/ Electrodes
- Other Systems
- Probes/Electrodes
- Rfa Probes
- Rfa Systems
By Procedure
- Laparoscopic Ablation
- Percutaneous Ablation
- Surgical Ablation
By Application
- Bone Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Other Applications
By End User
- Ascs
- Cancer Care Centers
- Hospitals & Clinics
- Other End Users
Target Audience
- Medical Device Manufacturers : Device companies need US market data to assess market size, growth potential, competitive positioning, and reimbursement landscape to guide product development, commercialization, and market entry strategies.
- Healthcare Investors & PE Firms : Investment professionals require validated US market forecasts, growth trajectories, and sector dynamics to evaluate acquisition targets, portfolio companies, and capital allocation decisions in oncology technology.
- Hospital & Healthcare Systems : US hospital networks and cancer centers need market intelligence to justify capital expenditures on ablation equipment, assess technology ROI, and plan interventional radiology service expansion.
- Consulting & Strategy Firms : Management consultants require US-specific market data to support client advisory work, competitive benchmarking, market entry strategies, and business case development for healthcare organizations.
- Regulatory & Compliance Officers : Healthcare compliance professionals need US market context, reimbursement policies, and adoption trends to navigate FDA regulations, insurance requirements, and clinical integration of ablation technologies.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise US market valuation ($402.6M in 2026) and verified 10.6% CAGR projections through 2031 to support strategic planning, investment decisions, and competitive positioning in the American tumor ablation sector.
- US-Specific Reimbursement Insights : Access detailed analysis of Medicare, Medicaid, and private insurance coverage policies affecting tumor ablation adoption across US healthcare systems, enabling informed pricing and market entry strategies.
- Regional Market Dynamics : Understand US-specific adoption patterns, physician preferences, hospital infrastructure readiness, and state-level regulatory variations that influence market penetration and revenue opportunities.
- Competitive Landscape Analysis : Identify leading US device manufacturers, emerging competitors, market share distribution, and differentiation strategies specific to the American oncology and interventional radiology markets.
- Growth Driver Identification : Leverage US-focused insights on aging demographics, cancer incidence trends, healthcare spending patterns, and technology adoption rates to identify high-potential market segments and expansion opportunities.
Frequently asked questions
What is the current size of the US tumor ablation market?
The US tumor ablation market is valued at $402.6 million in 2026 and is projected to reach $665.2 million by 2031.
What is the expected growth rate of the US tumor ablation market?
The US tumor ablation market is expected to grow at a compound annual growth rate (CAGR) of 10.6% from 2026 to 2031.
What factors are driving growth in the US tumor ablation market?
Key drivers include rising incidence of solid tumors, increasing adoption of minimally invasive procedures, technological innovation in ablation systems, and strong FDA regulatory support for new technologies.
Which ablation technologies are most prevalent in the US market?
The US market features radiofrequency ablation, microwave ablation, and cryoablation as the primary technologies, with continuous innovation enhancing efficacy and safety profiles.
How does the US market compare to global tumor ablation trends?
The US market grows at 10.6% CAGR, slightly below the global rate of 11.4%, reflecting mature market dynamics and established clinical practices in the US healthcare system.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current tumor ablation market size. First, extensive secondary research was conducted to gather information on the market, including related and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, Companies House documents, investor presentations, and SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the tumor ablation market. It was also used to obtain important information about key players and market classification and segmentation according to industry trends to the bottom-most level, as well as key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the tumor ablation market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.
A breakdown of the primary respondents for the tumor ablation market is provided below:
Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global tumor ablation market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players. Also, the global tumor ablation market was split into various segments and sub-segments based on:
- List of major players operating in the products market at the regional and/or country level
- Product mapping of various tumor ablation manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from tumor ablation (or the nearest reported business unit/product category)
- Revenue mapping of major players
- Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
- Summation of the market value of all segments/subsegments to arrive at the global tumor ablation market.
Tumor Ablation Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the overall size of the global tumor ablation market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.
Market Definition
Tumor ablation is a minimally invasive surgical procedure used to remove or destroy cancerous tissue from the affected area as part of cancer management and treatment. The targeted tissue is subjected to ablating energy through surgical, laparoscopic, or percutaneous methods. This technique is commonly used for treating liver, bone, lung, kidney, prostate, and other types of cancer.
Key Stakeholders
- Tumor ablation system and electrode manufacturers, suppliers, and providers
- Contract research organizations (CROs)
- Research & development (R&D) companies
- Academic & research institutions
- Regulatory agencies
- Contract manufacturing organizations (CMOs)
- Environmental & safety regulatory bodies
- Hospitals & clinics
- Interventional radiologists
Report Objectives
- To define, describe, and forecast the tumor ablation market by technology, product, procedure, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions in the market
- To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and analyze their market shares
- To analyze competitive developments such as product launches, agreements, expansions, and acquisitions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players based on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe tumor ablation market into Russia, Switzerland, Denmark, Austria, and others
- Further breakdown of the Rest of Latin America tumor ablation market into Argentina, Colombia, Chile, Ecuador, and others
- Further breakdown of the Rest of Asia Pacific tumor ablation market into Malaysia, Singapore, New Zealand, and others
Competitive Landscape Assessment
- Market share analysis, by region (North America and Europe), which provides market shares of the top 3-5 key players in the tumor ablation market
- Competitive leadership mapping for established players in the US
Get the Full Tumor Ablation Market Report
Full forecast, segment splits, and company analysis for all Tumor Ablation Market.
- Canada Tumor Ablation Market
- Germany Tumor Ablation Market
- France Tumor Ablation Market
- UK Tumor Ablation Market
- Italy Tumor Ablation Market
- Spain Tumor Ablation Market
- China Tumor Ablation Market
- Japan Tumor Ablation Market
- India Tumor Ablation Market
- Australia Tumor Ablation Market
- South Korea Tumor Ablation Market
- Brazil Tumor Ablation Market
- Mexico Tumor Ablation Market
- Rest Of Europe Tumor Ablation Market
- Rest Of Asia Pacific Tumor Ablation Market
- Rest Of Latin America Tumor Ablation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
